Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients

J Am Acad Dermatol. 2021 Dec;85(6):e371-e372. doi: 10.1016/j.jaad.2019.04.039. Epub 2019 Apr 20.

Authors

Spyros M Siscos¹, Brett C Neill¹, Isadore S Tarantino¹, Daniel J Aires¹, Anand Rajpara²

Affiliations

¹ Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas.
² Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas. Electronic address: arajpara@kumc.edu.

PMID: 31015010
DOI: 10.1016/j.jaad.2019.04.039

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Infective Agents* / therapeutic use
Dapsone / therapeutic use
Drug Therapy, Combination
Humans
Pneumonia, Pneumocystis* / prevention & control
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

Anti-Infective Agents
Trimethoprim, Sulfamethoxazole Drug Combination
Dapsone